Patents by Inventor Lipeng Xu

Lipeng Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240139809
    Abstract: An apparatus and method for preparing high-purity spherical magnesium and/or high-purity magnesium powder are provided. The apparatus includes a vertical furnace body, a heating zone, and a condensing zone, where a periphery of the condensing zone is provided with a first thermal insulation device and a second thermal insulation device sequentially from bottom to top, and each of the first thermal insulation device and the second thermal insulation device is removably arranged; the periphery of the condensing zone is further provided with a liquid cooling device; a gas inlet and a gas outlet are formed in the condensing zone; and an inner wall of the condensing zone is provided with an arrangement structure configured to arrange a collection device. A heating temperature of a material and condensation conditions in the condensing zone are controlled to make an evaporated magnesium vapor condensed on the collection device in the condensing zone.
    Type: Application
    Filed: January 11, 2024
    Publication date: May 2, 2024
    Applicant: KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Yang TIAN, Dong LIANG, Bin YANG, Baoqiang XU, Dachun LIU, Fei WANG, Yifu LI, Wenlong JIANG, Yong DENG, Jian WU, Lipeng WANG
  • Patent number: 11903923
    Abstract: The present invention provides uses of an andrographolide derivative in preparation of a medicament for preventing and treating inflammatory bowel disease. The andrographolide derivative AL-1 has the mechanisms, for the treatment of ulcerative colitis, of scavenging of free radicals, inhibition of NF-?B signaling pathway activation and COX-2 expression, activation of PPAR-? expression, and thus can prevent the transcription and expression of inflammatory-related genes to improve the conditions of inflammation. AL-1 can be used as a medicine for the treatment of inflammatory bowel disease and can be formulated to various dosage forms with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: February 20, 2024
    Inventors: Yuqiang Wang, Lipeng Xu, Pei Yu, Yewei Sun, Zaijun Zhang, Gaoxiao Zhang, Peng Yi
  • Publication number: 20220202812
    Abstract: The present invention relates to the use of ligustrazine nitrone derivatives and pharmaceutical composition thereof for the treatment and prevention of diseases of diabetic complications, which include renal anemia. The ligustrazine nitrone derivatives have the structure of the general formula (I). Experimental results indicated that the ligustrazine nitrone derivatives can significantly increase the levels of serum iron and erythropoietin in STZ induced SD rats and spontaneously hypertensive rats, and can be used for treating and preventing renal anemia caused by decrease in renal EPO production and/or concomitant iron deficiency. Therefore, the ligustrazine nitrone derivatives can be made into various dosage forms with a drug carrier. The derivatives can be prepared into various dose forms together with drug carriers.
    Type: Application
    Filed: November 3, 2021
    Publication date: June 30, 2022
    Applicant: QINGDAO HAILAN PHARMACEUTICALS CO., LTD.
    Inventors: Yuqiang Wang, Yewei Sun, Lipeng Xu, Mei Jing, Zaijun Zhang, Gaoxiao Zhang, Pei Yu, Peng Yi
  • Patent number: 11197855
    Abstract: A use of of ligustrazine nitrone derivatives and a pharmaceutical composition thereof in the preparation of medicine for preventing and treating diabetic complication diseases. The ligustrazine nitrone derivatives can be prepared into various dose forms together with drug carriers.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: December 14, 2021
    Inventors: Yuqiang Wang, Yewei Sun, Lipeng Xu, Mei Jing, Zaijun Zhang, Gaoxiao Zhang, Pei Yu, Peng Yi
  • Publication number: 20200155548
    Abstract: A use of of ligustrazine nitrone derivatives and a pharmaceutical composition thereof in the preparation of medicine for preventing and treating diabetic complication diseases. The ligustrazine nitrone derivatives can be prepared into various dose forms together with drug carriers.
    Type: Application
    Filed: May 25, 2018
    Publication date: May 21, 2020
    Applicant: QINGDAO HAILAN PHARMACEUTICALS CO., LTD.
    Inventors: Yuqiang Wang, Yewei Sun, Lipeng Xu, Mei Jing, Zaijun Zhang, Gaoxiao Zhang, Pei Yu, Peng Yi
  • Publication number: 20180147181
    Abstract: The present invention provides uses of an andrographolide derivative in preparation of a medicament for preventing and treating inflammatory bowel disease. The andrographolide derivative AL-1 has the mechanisms, for the treatment of ulcerative colitis, of scavenging of free radicals, inhibition of NF-?B signaling pathway activation and COX-2 expression, activation of PPAR-? expression, and thus can prevent the transcription and expression of inflammatory-related genes to improve the conditions of inflammation. AL-1 can be used as a medicine for the treatment of inflammatory bowel disease and can be formulated to various dosage forms with a pharmaceutically acceptable carrier.
    Type: Application
    Filed: July 4, 2016
    Publication date: May 31, 2018
    Applicant: GUANGZHOU MAGPIE PHARMACEUTICALS CO., LTD.
    Inventors: Yuqiang Wang, Lipeng Xu, Pei Yu, Yewei Sun, Zaijun Zhang, Gaoxiao Zhang, Peng Yi